Two sets of myeloma real-world and clinical observations sharpen how earlier and extended use of cell and T-cell engagers may be managed. A real-world study reports that ciltacabtagene autoleucel (cilta-cel) achieved a 98.0% overall response rate in relapsed or refractory multiple myeloma treated after one to three prior therapies, alongside deep minimal residual disease clearance. Separately, an observational correspondence in *Experimental Hematology and Oncology* describes six patients who remained on extended-interval teclistamab and talquetamab without repeating step-up dosing across 8 to 12 week gaps. The authors report no acute inflammatory toxicities during those extended dosing windows, despite high rates of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome during initial step-up periods. Together, the reports point toward more aggressive treatment sequencing and potentially simplified scheduling—provided patients have already achieved deep response and are monitored for late toxicities including infection risk and cytopenias.
Get the Daily Brief